Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine and DHEA for Hypoglycemia Defense in T1DM
NCT03228732Phase 1Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Dec 2017
- Primary completion
- Sep 2026
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fluoxetine and dehydroepiandrosterone in type 1 diabetes mellitus (T1D), sponsored by University of Maryland, Baltimore. Started Dec 2017; status: recruiting.
02
Drugs
fluoxetinedehydroepiandrosterone
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03228732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228732.